| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2019-04-08 | Sangamo Therapeutics (USA-CA) | $136.3 million | public offering | Private placement | ||
| 2018-10-18 | Oxford Nanopore Technologies (UK) | £50 million ( $66 million ) | private placement | Amgen (USA - CA) | Technology - Services | Private placement |
| 2018-10-18 | Krystal Biotech (USA - PA) | $60.0 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2018-10-17 | Iovance Biotherapeutics (USA - CA) | $252 million | private placement | Cancer - Oncology | Private placement | |
| 2018-10-17 | Acticor Biotech (France) | € 15.3 million | series B financing round | Newton BioCapital (Belgium) CapDecisif Management (France) Mirae Capital (South Korea) CMS Medical Venture Investment (China) A&B (China) | Cerebrovascular diseases | Series B financing round |
| 2018-10-10 | Secarna Pharmaceuticals (Germany) | grant | European Commission’s Horizon 2020 programme | Rare diseases - Fibrotic diseases - Lung diseases | Grant | |
| 2018-10-10 | Allogene Therapeutics (USA - CA) | $324.0 million | IPO | Cancer - Oncology | IPO | |
| 2018-10-10 | Allogene Therapeutics (USA - CA) | $324 million | IPO | Cancer - Oncology | IPO | |
| 2018-10-10 | Histogenics (USA - MA) | $15.4 million | private placement | Regenerative Medicine - Bone diseases | Private placement | |
| 2018-10-10 | RoslinCT (UK) Reprocell (UK) | £1.2 million | grant | Innovate UK (UK) | Technology - Services | Grant |
| 2018-10-05 | Epizyme (USA - MA) | $86.25 million | private placement | Cancer - Oncology - Rare diseases | Private placement | |
| 2018-10-05 | Alligator Bioscience (Sweden) | 500 000 SEK (€ 47 845) | grant | Vinnova, Swedish Governmental Agency for Innovation Systems (Sweden) | Cancer - Oncology | Grant |
| 2018-09-28 | KSQ Therapeutics (USA - MA) | $80 million | series C financing round | Flagship Pioneering (USA - MA) Polaris Partners (USA - MA) ARCH Venture Partners (USA - IL) Alexandria Equities (USA - CA) Baillie Gifford (UK) Cowen Healthcare Investments (USA - NY) Invus (USA - NY) Lilly Asia Ventures (China) | Cancer - Oncology - Immunological diseases - Rare diseases | Series C financing round |
| 2018-09-26 | Minoryx Therapeutics (Spain) | €21.3 million | series B financing round | Chiesi Ventures (Italy) Caixa Capital Risc (Spain) HealthEquity (Spain) Fund+ (Belgium) Idinvest Partners (France) Kurma Partners (France) Sambrinvest (Belgium) Kurma Partners (France) Ysios Capital (Spain) SFPI-FPIM, S.R.I.W | Rare diseases | Series B financing round |
| 2018-09-20 | Fate Therapeutics (USA - CA) | private placement | Cancer - Oncology - Immunological diseases | Private placement | ||
| 2018-09-20 | Y-mAbs Therapeutics (USA - NY) | IPO | Cancer - Oncology | IPO | ||
| 2018-09-12 | CODA Biotherapeutics (USA - CA) | $19 million | series A financing round | MPM Capital (USA - MA) Versant Ventures (USA - CA) Astellas Venture Management (USA - CA) Novartis (Switzerland) | Neurological diseases - CNS diseases | Series A financing round |
| 2018-09-12 | Exocobio (Republic of Korea) | $27 million | series B financing round | Seven Tree Equity Partners (Republic of Korea) CSQUARED Global Asset Management (Republic of Korea) TS Investment Partners (Dubai) K2 Investment, Intervest (Republic of Korea) KDB Capital (Republic of Korea) Atinum Investment (Republic of Korea) GU Equity Partners (Republic of Korea) QUANTUM Ventures Korea (Republic of Korea) Platinum technology Investment (Republic of Korea) | Autoimmune diseases - Dermatological diseases | Series B financing round |
| 2018-09-07 | Oasmia Pharmaceutical (Sweden) | SEK 35.2 million | private placement | Cancer - Oncology | Private placement | |
| 2018-09-06 | Twentyeight-Seven Therapeutics (USA - MA) | $65 million | series A financing round | MPM Capital (USA - MA) Novartis Venture Fund (USA - MA) Johnson & Johnson Innovation – JJDC (USA - NJ) Vertex Ventures (USA - CA) Longwood Fund (USA - MA) Astellas Venture Management (USA - CA) | Cancer - Oncology | Series A financing round |
